| Type | Subsidiary |
| Parent Company | Biogen |
| HQ | Newton, MA, US |
| Founded | 2008 |
| Website | karyopharm.com |
| Cybersecurity rating | CMore |
Karyopharm Therapeutics was founded in 2008 and is headquartered in Newton, MA, US
Viewing summary data as a guest
Sign up for free to see all dataKey People/Management at Karyopharm Therapeutics
Sharon Shacham
President and Chief Scientific Officer, Founder
Garen Bohlin
Director
Brian Austad
Senior Vice President, Pharmaceutical Sciences
Mikael Dolsten
Director
Yosef Landesman
Senior Vice President, Research and Translational Medicine
Barry E. Greene
Lead Director
Karyopharm Therapeutics Office Locations
Karyopharm Therapeutics has offices in Newton, München and Tel Aviv-Yafo
Newton, MA, US (HQ)
85 Wells Ave
München, DE
9 Franziska-Bilek-Weg
Tel Aviv-Yafo, IL
Yigal Alon St 94
Karyopharm Therapeutics Financials and Metrics
Summary Metrics
Founding Date | 2008 |
Total Funding | $248.7 m |
Investors | New Leaf Venture Partners, Delphi Ventures, Foresite Capital |
Karyopharm Therapeutics is a subsidiary of Biogen
Karyopharm Therapeutics Revenue
Karyopharm Therapeutics's revenue was reported to be $108.09 m in FY, 2020
Annual
Quarterly
| USD | Q3, 2013 | Q1, 2014 | Q2, 2014 | Q3, 2014 | Q1, 2015 | Q2, 2015 | Q3, 2015 | Q1, 2016 | Q2, 2016 | Q3, 2016 | Q1, 2017 | Q2, 2017 | Q3, 2017 | Q1, 2018 | Q2, 2018 | Q3, 2018 | Q1, 2019 | Q2, 2019 | Q3, 2019 | Q1, 2020 | Q2, 2020 | Q3, 2020 | Q1, 2021 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Revenue | 171.0k | 21.0k | 21.0k | 150.0k | 75.0k | 59.0k | 48.0k | 68.0k | 19.9m | 239.0k | 155.0k | 9.5m | 13.1m | 18.1m | 33.5m | 21.3m | 23.3m | ||||||
Cost of goods sold | 1.0m | ||||||||||||||||||||||
Gross profit | 12.1m | ||||||||||||||||||||||
Gross profit Margin, % | 92% |
- Source: SEC Filings
Annual
Quarterly
| USD | Q3, 2013 | Q1, 2014 | Q2, 2014 | Q3, 2014 | Q1, 2015 | Q2, 2015 | Q3, 2015 | Q1, 2016 | Q2, 2016 | Q3, 2016 | Q1, 2017 | Q2, 2017 | Q3, 2017 | Q1, 2018 | Q2, 2018 | Q3, 2018 | Q1, 2019 | Q2, 2019 | Q3, 2019 | Q1, 2020 | Q2, 2020 | Q3, 2020 | Q1, 2021 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Cash | 52.9m | 144.9m | 132.3m | 227.1m | 51.5m | 24.2m | 43.5m | 42.2m | 37.7m | 43.9m | 25.6m | 55.4m | 54.5m | 37.5m | 119.0m | 101.6m | 83.5m | 75.5m | 168.0m | 202.2m | 103.1m | 82.3m | |
Accounts Receivable | 7.9m | 9.3m | 9.6m | ||||||||||||||||||||
Prepaid Expenses | 658.0k | 2.7m | 3.0m | 4.2m | 2.9m | 4.1m | 3.1m | 1.7m | 1.5m | 3.4m | 2.1m | 2.1m | 2.1m | 2.4m | 3.4m | 4.8m | 7.0m | 5.7m | 5.3m | 7.6m | 8.0m | 8.2m | |
Inventories | 100.0k | 970.0k | 1.7m | 2.0m |
- Source: SEC Filings
Annual
| USD | FY, 2013 | FY, 2014 | FY, 2015 | FY, 2016 | FY, 2017 | FY, 2018 | FY, 2019 | FY, 2020 |
|---|---|---|---|---|---|---|---|---|
Net Income | (33.9m) | (75.8m) | (118.2m) | (109.6m) | (129.0m) | (178.4m) | (199.6m) | (196.3m) |
Depreciation and Amortization | 144.0k | 323.0k | 634.0k | 717.0k | 713.0k | 735.0k | 974.0k | 972.0k |
Inventories | (346.0k) | (2.6m) | ||||||
Accounts Payable | 664.0k | 4.5m | (2.4m) | 945.0k | 909.0k | (1.4m) | (3.3m) | 3.5m |
Quarterly
| USD | Q3, 2013 | Q1, 2014 | Q2, 2014 | Q3, 2014 | Q1, 2015 | Q2, 2015 | Q3, 2015 | Q1, 2016 | Q2, 2016 | Q3, 2016 | Q1, 2017 | Q2, 2017 | Q3, 2017 | Q1, 2018 | Q2, 2018 | Q3, 2018 | Q1, 2019 | Q2, 2019 | Q3, 2019 | Q1, 2020 | Q2, 2020 | Q3, 2020 | Q1, 2021 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Net Income | (21.8m) | (13.7m) | (30.1m) | (49.8m) | (26.1m) | (58.8m) | (89.1m) | (27.1m) | (57.2m) | (82.6m) | (29.9m) | (59.3m) | (89.9m) | (38.5m) | (72.1m) | (120.2m) | (66.2m) | (109.6m) | (150.9m) | (52.9m) | (99.4m) | (152.9m) | (57.4m) |
Depreciation and Amortization | 106.0k | 43.0k | 85.0k | 191.0k | 136.0k | 292.0k | 457.0k | 179.0k | 358.0k | 537.0k | 183.0k | 363.0k | 539.0k | 169.0k | 353.0k | 541.0k | 245.0k | 487.0k | 730.0k | 242.0k | 480.0k | 715.0k | 235.0k |
Inventories | (100.0k) | (624.0k) | (1.3m) | (1.7m) | (552.0k) | ||||||||||||||||||
Accounts Payable | 673.0k | 1.5m | 1.7m | 362.0k | 268.0k | (1.8m) | (2.1m) | 294.0k | 233.0k | (1.7m) | (522.0k) | (1.5m) | (2.9m) | (773.0k) | (1.9m) | (3.4m) | (2.0m) | (3.2m) | (1.2m) | 711.0k | 903.0k | 1.4m | (1.4m) |
- Source: SEC Filings
| USD | Q3, 2013 |
|---|---|
Financial Leverage | -1.2 x |
Karyopharm Therapeutics Cybersecurity Score
Karyopharm Therapeutics Environment, Social & Governance (ESG) Ratings
Karyopharm Therapeutics Online and Social Media Presence
Karyopharm Therapeutics's Trends
Karyopharm Therapeutics Company Culture
Overall Culture
B
78/100
CEO Rating
C+
72/100
Compensation
A+
90/100
Diversity
B-
77/100
Karyopharm Therapeutics News and Updates
December 21, 2020
Antengene Announces its U.S. Partner, Karyopharm Therapeutics Inc., has received FDA Approval of XPOVIO® (Selinexor) as a Treatment for Patients with Multiple Myeloma After At Least One Prior Therapy
SHANGHAI and HONG KONG, Dec. 20, 2020 /PRNewswire/ -- Antengene Corporation Limited ("Antengene", SEHK: 6996.HK) today announced that the U.S. Food and Drug Administration (FDA) has approved the supplemental New Drug Application (sNDA) submitted by its partner Karyopharm Therapeutics Inc....
September 20, 2019
KARYOPHARM DEADLINE ALERT: Faruqi & Faruqi, LLP Encourages Investors Who Suffered Losses Exceeding $50,000 In Karyopharm Therapeutics Inc. To Contact The Firm
New York, NY - (NewMediaWire) - September 20, 2019 - Faruqi & Faruqi, LLP, a leading national securities law firm, reminds investors in Karyopharm Therapeutics Inc. (“Karyopharm” or the “Company”) (NASDAQ: KPTI) of the September 23, 2019 deadline to seek the role of lead plaintiff in a fede…
August 02, 2019
ROSEN, A HIGHLY RANKED LAW FIRM, Announces Filing of Securities Class Action Lawsuit Against Karyopharm Therapeutics Inc.; Encourages Investors with Losses in Excess of $100K to Contact the Firm - KPTI
NEW YORK, Aug. 2, 2019 /PRNewswire/ -- Rosen Law Firm, a global investor rights law firm, announces the filing of a class action lawsuit on behalf of purchasers of the securities of Karyopharm Therapeutics Inc. (NASDAQ: KPTI) from March 2, 2017 through February 22, 2019, inclusive (the...
July 27, 2019
KARYOPHARM SHAREHOLDER ALERT BY FORMER LOUISIANA ATTORNEY GENERAL: Kahn Swick & Foti, LLC Reminds Investors with Losses in Excess of $100,000 of Lead Plaintiff Deadline in Class Action Lawsuit Against Karyopharm Therapeutics Inc. - KPTI
NEW ORLEANS, July 26, 2019 /PRNewswire/ -- Kahn Swick & Foti, LLC ("KSF") and KSF partner, former Attorney General of Louisiana, Charles C. Foti, Jr., remind investors that they have until September 23, 2019 to file lead plaintiff applications in a securities class action lawsuit against...
July 25, 2019
LEAD PLAINTIFF DEADLINE ALERT: Faruqi & Faruqi, LLP Encourages Investors Who Suffered Losses Exceeding $50,000 In Karyopharm Therapeutics Inc. To Contact The Firm
NEW YORK, NY - (NewMediaWire) - July 25, 2019 - Faruqi & Faruqi, LLP, a leading national securities law firm, reminds investors in Karyopharm Therapeutics Inc. (NASDAQ: KPTI) ("Karyopharm" or the "Company") of the September 23, 2019 deadline to seek the role of lead plaintiff in a federal s…
July 23, 2019
Bernstein Litowitz Berger & Grossmann LLP Announces Securities Class Action Suit Filed Against Karyopharm Therapeutics Inc. And Certain Of Its Senior Executives, Its Board Of Directors, And Underwriters Of Its April 2017 And May 2018 Stock Offerings
NEW YORK, July 23, 2019 /PRNewswire/ -- Bernstein Litowitz Berger & Grossmann LLP ("BLB&G") today announced that it filed a securities class action lawsuit on behalf of its client Allegheny County Employees' Retirement System ("ACERS") against Karyopharm Therapeutics Inc. ("Karyopharm" or ..…
Karyopharm Therapeutics Blogs
May 03, 2021
Karyopharm Reports First Quarter 2021 Financial Results and Highlights Recent Company Progress
-- Total Revenues of $23.3 Million for the First Quarter of 2021; XPOVIO® (selinexor) Net Product Sales of $21.7 Million --
May 03, 2021
Karyopharm Announces the Appointment of Richard Paulson as President and Chief Executive Officer
-- Richard Paulson, Recent Chief Executive Officer of Ipsen North America and Former Vice President and General Manager of Oncology at Amgen, Brings Wealth of Commercial Leadership and Global Strategic Experience --
April 28, 2021
Karyopharm to Report First Quarter 2021 Financial Results on May 3, 2021
-- Conference Call Scheduled for Monday, May 3, 2021, at 8:30 a.m. ET --
April 26, 2021
Karyopharm Announces European Medicines Agency's Validation of its Type II Variation Marketing Authorization Application for NEXPOVIO® (selinexor) in Combination with Velcade® (bortezomib) and Dexamethasone for the Treatment of Adult Patients with Multiple Myeloma
- EMA Regulatory Decision Expected in the Fourth Quarter of 2021 -
April 19, 2021
Karyopharm Announces Publication of Health-Related Quality of Life Outcomes from Phase 3 SEAL Study of Selinexor in Advanced Unresectable Dedifferentiated Liposarcoma in Future Oncology
- Treatment with Selinexor Demonstrated Several Potential Clinical Advantages Compared to Placebo, Including Reduction in Pain, Longer Time to Marked Clinical Deterioration of Pain and Longer Median Time to Next Treatment -
March 29, 2021
Karyopharm Receives Conditional Marketing Authorization from the European Commission for NEXPOVIO® (selinexor) in Combination with Dexamethasone for the Treatment of Adult Patients with Relapsed and or Refractory Multiple Myeloma
-- NEXPOVIO is the First and Only Nuclear Export Inhibitor Authorized by the European Commission --
Karyopharm Therapeutics Frequently Asked Questions
When was Karyopharm Therapeutics founded?
Karyopharm Therapeutics was founded in 2008.
Who are Karyopharm Therapeutics key executives?
Karyopharm Therapeutics's key executives are Sharon Shacham, Garen Bohlin and Brian Austad.
How many employees does Karyopharm Therapeutics have?
Karyopharm Therapeutics has 464 employees.
What is Karyopharm Therapeutics revenue?
Latest Karyopharm Therapeutics annual revenue is $108.1 m.
What is Karyopharm Therapeutics revenue per employee?
Latest Karyopharm Therapeutics revenue per employee is $232.9 k.
Who are Karyopharm Therapeutics competitors?
Competitors of Karyopharm Therapeutics include Jiangsu Hansoh Pharmaceutical Group, Takeda Oncology and Celltrion Healthcare.
Where is Karyopharm Therapeutics headquarters?
Karyopharm Therapeutics headquarters is located at 85 Wells Ave, Newton.
Where are Karyopharm Therapeutics offices?
Karyopharm Therapeutics has offices in Newton, München and Tel Aviv-Yafo.
How many offices does Karyopharm Therapeutics have?
Karyopharm Therapeutics has 3 offices.
Learn about Craft real-time company insights
Receive alerts for 300+ data fields across thousands of companies